An overview of insulin glargine
Authors:
- 1 September 2002
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 18 (S3) , S57-S63
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.Diabetes, 2000
- Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.Diabetes Care, 2000
- Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.Diabetes, 2000
- Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.Diabetes Care, 2000
- The Long Acting Human Insulin Analog HOE 901: Characteristics of Insulin Signalling in Comparison to Asp(B10) and Regular InsulinHormone and Metabolic Research, 1998
- Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cellsEuropean Journal of Pharmacology, 1997
- Effect of carbon deposits on the properties of co/y-zeolite catalysts for co hydrogenationKorean Journal of Chemical Engineering, 1989
- Basal and 24-h C-peptide and insulin secretion rate in normal manDiabetologia, 1987
- Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.BMJ, 1978
- Crystalline and Amorphous Insulin-Zinc Compounds with Prolonged ActionScience, 1952